|
Home
Pearls
More
Features
More
Reviews
Opportunities
Editor
in Chief
Order
Form
Site
Map
Contact Me
| |
Match the chemotherapeutic agent to their side
effect. (Each choice may be used once, more than once, or not at all.
- Adriamycin
(Doxorubicin, Daunorubicin)
|
- Hemorrhagic cystitis
|
- Ifosfamide
|
- Pulmonary fibrosis
|
- Cisplatin
|
- Cardiotoxicity
|
- Cytoxan
(cyclophosphamide)
|
- Neurotoxicity
|
- Bleomycin
|
- Nephrotoxicity
|
- Vincristine
|
- Conjunctivitis
|
- Ara-c (cytarabine)
|
- Hemolytic uremic syndrome
|
- Methotrexate
|
|
- Mitomycin C
|
|
Top of Page
Return to Features Page
ANSWERS:
 |
maintaining total cumulative
dose > 450 mg/m2 will limit the cardiotoxicity of adriamycin
(CHF CMP). Ejection
fraction should be evaluated before administering this agent. |
 |
, Ifosfamide
is more potent than cytoxan in causing hemorrhagic cystitis.
Preventive measures are intravenous fluid
(or by mouth) and Mesna (may
deactivate acrolein, which is thought to be the metabolite of Ifosfamide
and cytoxan that injures the epithelial lining of the gastrointestinal
tract). |
 |
Cisplatin
is one of the most potent emetogenic chemotherapeutic agents.
It can cause electrolyte wasting (decreased Mg++, decreased K+) in
addition to renal failure. Intravenous hydration is the key for
prevention. |
 |
, see Answer 2 for explanation |
 |
, Bleomycin
toxicity increases (pneumontis, fibrosis, hypoxia) with increase total
cumulative dose approaching 400 mg. |
 |
, Along with 5-FU can both
cause severe mucositis (GI tract). |
 |
, Mitomycin
is responsible for ~85% of all chemo induced HUS. The only
intervention proven somehow helpful is hemoperfusion over a SPA (Staph
protein A) column. |
Top of Page
Return
to Features Page
|
